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ABSTRACT 
Nα-terminal arginylation 
(Nt-arginylation) of proteins is mediated 
by the Ate1 arginyltransferase 
(R-transferase), a component of the 
Arg/N-end rule pathway. This proteolytic 
system recognizes proteins containing 
N-terminal degradation signals called 
N-degrons, polyubiquitylates these 
proteins, and thereby causes their 
degradation by the proteasome. The 
definitively identified (“canonical”) 
residues that are Nt-arginylated by 
R-transferase are N-terminal Asp, Glu 
and (oxidized) Cys. Over the last decade, 
several publications suggested (i) that Ate1 
can also arginylate non-canonical 
N-terminal residues; (ii) that Ate1 is 
capable of arginylating not only α-amino 
groups of N-terminal residues but also 
γ-carboxyl groups of internal 
(non-N-terminal) Asp and Glu; and 
(iii) that some isoforms of Ate1 are specific 
for substrates bearing N-terminal Cys 
residues. In the present study, we 
employed arrays of immobilized 
11-residue peptides and pulse-chase assays 
to examine the substrate specificity of 
mouse R-transferase. We show that amino 
acid sequences immediately downstream 
of a substrate’s canonical 
(Nt-arginylatable) N-terminal residue, 
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particularly a residue at position 2, can 
affect the rate of Nt-arginylation by 
R-transferase and thereby the rate of 
degradation of a substrate protein. We 
also show that the four major isoforms of 
mouse R-transferase have similar 
Nt-arginylation specificities in vitro, 
contrary to the claim about specificity of 
some Ate1 isoforms for N-terminal Cys. In 
addition, we found no evidence for a 
significant activity of the Ate1 
R-transferase toward previously invoked 
non-canonical N-terminal or internal 
amino acid residues. Together, our results 
raise technical concerns about earlier 
studies that invoked non-canonical 
arginylation specificities of Ate1. 
 
The N-end rule pathway is a set of 
intracellular proteolytic systems whose 
unifying feature is the ability to recognize 
and polyubiquitylate proteins containing 
N-terminal (Nt) degradation signals called 
N-degrons, thereby causing the processive 
degradation of these proteins by the 
proteasome (Fig. 1A, B) (1-13). Recognition 
components of the N-end rule pathway are 
called N-recognins. In eukaryotes, 
N-recognins are E3 ubiquitin (Ub) ligases 
that can target N-degrons. Some N-recognins 
contain several substrate-binding sites, and 
thereby can recognize (bind to) not only 
N-degrons but also specific internal 
(non-N-terminal) degradation signals 
(Fig. 1A) (14-18). The main determinant of a 
protein’s N-degron is either an unmodified or 
chemically modified N-terminal residue. 
Another determinant of an N-degron is an 
internal Lys residue(s). It functions as a site 
of protein’s polyubiquitylation, is often 
engaged stochastically (in competition with 
other “eligible” lysines), and tends to be 
located in a conformationally disordered 
region (2,9,19,20). Bacteria also contain the 
N-end rule pathway, but Ub-independent 
versions of it (21-26). 
Regulated degradation of proteins and 
their natural fragments by the N-end rule 
pathway has been shown to mediate a 
strikingly broad range of biological 
functions, including the sensing of heme 
(27), nitric oxide (NO), oxygen (4,7,28,29), 
and short peptides (14,15,30-35); the control, 
through subunit-selective degradation, of the 
input stoichiometries of subunits in 
oligomeric protein complexes (5,36); the 
elimination of misfolded and otherwise 
abnormal proteins (6,17,18,37-41); the 
degradation of specific proteins after their 
translocation to the cytosol from membrane-
enclosed compartments such as mitochondria 
(42); the regulation of apoptosis and 
repression of neurodegeneration (43-46); the 
regulation of DNA repair, transcription, 
replication, and chromosome 
cohesion/segregation (14,16,47-52); the 
regulation of G proteins, cytoskeletal 
proteins, autophagy, peptide import, meiosis, 
immunity, circadian rhythms, fat 
metabolism, cell migration, cardiovascular 
development, spermatogenesis, and 
neurogenesis (4,14,53-59); the functioning of 
adult organs, including the brain, muscle, 
testis, and pancreas (57,60-64); and the 
regulation of leaf and shoot development, 
leaf senescence, oxygen/NO sensing, and 
many other processes in plants (Fig. 1A, B) 
(7-13,22,28,65-69). 
In eukaryotes, the N-end rule 
pathway consists of two branches. One 
branch, called the Ac/N-end rule pathway, 
targets proteins for degradation through their 
Nα-terminally acetylated (Nt-acetylated) 
residues (Fig. 1B) (5,6,13,36,56,70,71). 
Degradation signals and E3 Ub ligases of the 
Ac/N-end rule pathway are called 
Ac/N-degrons and Ac/N-recognins, 
respectively. Nt-acetylation of cellular 
proteins is apparently irreversible, in contrast 
to cycles of acetylation-deacetylation of 
proteins’ internal Lys residues. About 90% 
of human proteins are cotranslationally 
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Nt-acetylated by ribosome-associated 
Nt-acetylases (72). Posttranslational 
Nt-acetylation takes place as well. 
Ac/N-degrons are present in many, possibly 
most, Nt-acetylated proteins (Fig. 1B). 
Natural Ac/N-degrons are regulated through 
their reversible shielding in cognate protein 
complexes (6,36,56). 
The pathway’s other branch, called 
the Arg/N-end rule pathway, targets specific 
unacetylated N-terminal residues (Fig. 1A) 
(4,6,29,42-44,54,73-75). The “primary” 
destabilizing N-terminal residues Arg, Lys, 
His, Leu, Phe, Tyr, Trp, and Ile are directly 
recognized by N-recognins. The unacetylated 
N-terminal Met, if it is followed by a bulky 
hydrophobic (Ф) residue, also acts as a 
primary destabilizing residue (Fig. 1A) (6). 
In contrast, the unacetylated N-terminal Asn, 
Gln, Asp, and Glu (as well as Cys, under 
some metabolic conditions) are destabilizing 
owing to their preliminary enzymatic 
modifications, which include N-terminal 
deamidation (Nt-deamidation) of Asn and 
Gln, and Nt-arginylation of Asp, Glu and 
oxidized Cys (Fig. 1A) (7-9,76). In the yeast 
Saccharomyces cerevisiae, the Arg/N-end 
rule pathway is mediated by the Ubr1 
N-recognin, a 225 kDa RING-type E3 Ub 
ligase and a part of the multisubunit targeting 
complex comprising the Ubr1-Rad6 and 
Ufd4-Ubc4/5 E2-E3 holoenzymes (9,77). In 
multicellular eukaryotes, several E3 Ub 
ligases, including Ubr1, function as 
N-recognins of the Arg/N-end rule pathway 
(8,9) (Fig. 1A). 
Nt-arginylation of proteins is 
mediated by the Ate1-encoded 
arginyltransferase (Arg-tRNA-protein 
transferase; R-transferase) (Fig. 1A) 
(3,4,27,78-81). The “canonical” (definitively 
identified and characterized) Nt-arginylatable 
residues are N-terminal Asp, Glu, and Cys, 
the latter after its oxidation to Cys-sulfinate 
or Cys-sulfonate through reactions that 
involve NO, oxygen, and/or N-terminal Cys 
oxidases (4,7,27,78,79,82,83). Because 
N-terminal Cys has to undergo two 
consecutive modifications, an oxidation and 
Nt-arginylation, before the recognition of a 
corresponding N-degron by N-recognins, 
Cys is classed as a “tertiary” destabilizing 
residue (Fig. 1A).  
In mammals such as mice, there are at 
least six isoforms of R-transferase, produced 
through alternative splicing of the Ate1 pre-
mRNA (Fig. 1C, D) (9,78,79). At present, 
about 20 mammalian proteins, including 
natural protein fragments, have been 
identified as either constitutively or 
conditionally short-lived physiological 
substrates of the Ate1 R-transferase and the 
post-arginylation part of the Arg/N-end rule 
pathway. All of these substrates have in 
common the presence of a canonical 
(Nt-arginylatable) N-terminal residue, either 
Asp, Glu or Cys (Fig. 1A) (4,29,42-
44,49,50,73,84,85). In addition, there are 
hundreds of mammalian proteins, including 
natural protein fragments, that are predicted 
to be Nt-arginylated, based on the presence, 
in a protein or its natural fragment, of 
N-terminal Asp, Glu, or Cys 
(7,43,44,49,73,86). 
Several publications over the last 
decade, largely by the laboratory of 
A. Kashina, have reported that Ate1 
R-transferase can also arginylate, to a 
significant extent, a variety of 
“non-canonical” (non-Asp, non-Glu, 
non-Cys) N-terminal residues in cellular 
proteins (87-92). The same group described 
evidence that some isoforms of R-transferase 
were specific for substrates bearing 
N-terminal Cys (93). Other recent 
publications by the same laboratory 
suggested, on the basis of mass spectrometric 
(MS) analyses, that the Ate1 R-transferase is 
capable of arginylating not only α-amino 
groups of specific N-terminal residues but 
also γ-carboxyl groups of internal 
(non-N-terminal) Asp or Glu (94,95). This 
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suggestion followed a report, by another 
group, that described a modified 13-residue 
neurotensin hormone that appeared to be 
arginylated at its internal Glu-4 residue (96). 
Thus far, studies by other laboratories failed 
to find evidence for either a significant 
arginylation of non-canonical N-terminal 
amino acid residues or a significant 
arginylation of internal residues (85,97-99). 
In the present work, we used purified 
isoforms of the mouse Ate1 R-transferase, 
arrays of C-terminally immobilized synthetic 
peptides, and pulse-chase degradation assays 
to address the substrate specificity of 
arginylation by mouse Ate1. We show here 
that a sequence immediately downstream of a 
substrate’s canonical (Nt-arginylatable) 
N-terminal residue, and particularly a residue 
at position 2, can significantly affect the rate 
of Nt-arginylation by R-transferase and 
thereby the rate of degradation of a substrate 
protein. We also show that the four major 
isoforms of the mouse R-transferase have 
similar substrate specificities in vitro, 
contrary to the earlier claim that some 
isoforms of Ate1 are specific for substrates 
bearing N-terminal Cys (93). Furthermore, 
and also contrary to the other cited reports 
(87-89,94,100,101), we found no evidence 
for a significant activity of the Ate1 
R-transferase toward the previously 
suggested non-canonical residues.  
A caveat to otherwise direct 
contradictions between our findings and 
those by the earlier studies is that our results 
were produced in vitro (with purified Ate1 
R-transferase and peptide arrays), whereas 
most reports about non-canonical 
arginylation of cellular proteins were about 
analyses of natural, in vivo-produced proteins 
(87-92,94-96). 
 
Results and Discussion 
Use of CelluSpots Peptide Arrays to 
Analyze the Substrate Specificity of 
R-transferase – CelluSpotsTM arrays are 
produced by the synthesis of C-terminally 
immobilized peptides on a modified cellulose 
support that is dissolvable in a trifluoroacetic 
acid solution, thereby allowing the 
synthesized peptides to be spotted onto 
coated microscope slides. This technology 
makes it possible to produce a number of 
virtually identical copies of a peptide array 
from a single set of peptide-synthesizing 
reactions (102). CelluSpots arrays have been 
successfully used to examine the specificity 
of histone-modifying enzymes for amino 
acid sequences in histones, to analyze, 
in vitro, the binding specificity of antibodies, 
to characterize specific binding of SH2 
(Src homology 2 domain) protein regions to 
phosphotyrosine-containing peptides, and to 
survey the specificities of phosphokinases 
and kinase inhibitors (103-105). 
 To analyze the substrate specificity of 
the mouse Ate1 R-transferase, we performed 
14C-arginylation assays using identical 
CelluSpots peptide arrays, each of which 
comprised 96 immobilized peptides that were 
largely 11 residues long (two peptides were 
12 residues long) (Fig. 2 and Table 1). To the 
best of our knowledge, CelluSpots have not 
been previously used to study arginylation. 
The unlimited sequence diversity of synthetic 
peptides, the availability of virtually identical 
copies of a given peptide array, and 
technically straightforward, reproducible 
conditions of arginylation assays make 
CelluSpots a particularly helpful method for 
analyzing the in vitro specificity of Ate1 
R-transferase isoforms (3,78-81). 
Amino acid sequences of 11-residue 
peptides in CelluSpots arrays were designed 
to examine several specificity aspects of the 
mouse R-transferase, including effects of a 
second-position residue of a substrate; effects 
of charge clusters immediately downstream 
of the (arginylatable) N-terminal residue; 
effects of the Pro residue (an imino acid) 
close to N-terminal residue; and the influence 
of oxidation of N-terminal Cys on its 
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efficacy as an acceptor of Arg in 
Ate1-catalyzed reactions. We also wished to 
address, using the conceptually independent 
and technically straightforward technology of 
peptide arrays, several earlier reports, based 
on mass-spectrometry (MS) data, that 
suggested the ability of Ate1 R-transferase to 
arginylate non-canonical amino acid 
residues, both N-terminal and internal ones 
(87,94,96).  
As a part of initial quality controls, 
and also to verify that peptides on CelluSpots 
arrays could actually serve as efficacious 
substrates of purified mouse Ate1 
R-transferase isoforms, the arginylation 
reaction was optimized on slides containing 
duplicate copies of a peptide array, in either 
the presence or the absence of a purified 
mouse Ate1 R-transferase isoform (Fig. 2 
and Experimental Procedures). The expected 
“positive” peptides (bearing canonical N-
terminal residues; see the Introduction) and 
the putative “negative” peptides (bearing 
non-canonical N-terminal residues) were 
interspersed with other peptides throughout a 
CelluSpots array (Fig. 2). Some peptides 
were included in duplicate, making it easier 
to assess the extent of variability of these 
arginylation assays within each assay. Spots 
A1-A24 and B1-B24 (Fig. 2) were of 
11-residue peptides whose sequences were 
variable over the first five residues and 
constant afterward, specifically Xaa1-Xaa2-
Xaa3-Xaa4-Xaa5-Xaa6-Gly-Pro-Ala-Ser-
Gly. The sequences of 11-residue peptides in 
other spots (C1-C24 and D1-D24) contained, 
in general, varying residues both before and 
after position 6, as described in Table 1. Two 
peptides, at C1 and C5, were 12 residues 
long (Fig. 2 and Table 1). 
Under the conditions used (see 
Experimental Procedures), the otherwise 
complete reaction mix that included 
L-[14C]-arginine (14C-Arg) but lacked the 
added Ate1 R-transferase resulted in a 
uniformly negligible level of 14C-Arg 
incorporation (Fig. 2B, left panel vs. right 
panel). In contrast, the same assay, with a 
virtually identical copy of CelluSpots array, 
but carried out in the presence of a purified 
Ate1 R-transferase isoform such as Ate11B7A 
(Fig. 1C), yielded high levels of 14C-Arg 
conjugation in spots whose peptides 
contained a canonical Nt-arginylatable 
residue such as N-terminal Asp (D) or Glu 
(E) (for example, Fig. 2B, right panel, spots 
A7, A8, A11, A12, B6-B11, C15, C23, D12, 
D13, D21, D22). These and related results 
(Figs. 2-5) illustrate high signal-to-noise 
levels and a broad dynamic range of 
CelluSpots arginylation assays. 
The autoradiogram in Fig. 2B (its 
panel on the right) exhibited negligible 
(undetectable) levels of 14C-Arg 
incorporation in “negative” spots, i.e., those 
containing 11-residue peptides with non-
canonical (non-Asp, non-Glu, non-Cys) 
N-terminal residues. Significantly longer 
autoradiographic exposures of the same or 
independently produced CelluSpots 
14C-arginylation assays allowed the detection 
of (low) 14C-Arg incorporation in the 
“negative” peptide spots of these arrays. 
Examples of background-level but detectable 
14C-Arg incorporation that can be seen upon 
longer autoradiographic exposures, are in 
Figs. 3A, 4B, and 5A. 
Interestingly, a comparably long 
autoradiographic overexposure of the 
otherwise complete 14C-Arg-containing 
reaction mix that lacked the added Ate1 
R-transferase still yielded negligible 
(undetectable visually) levels of 14C-Arg 
incorporation (Fig. 2B, left panel, and data 
not shown). These data (Figs. 2-5 and Fig. 8) 
suggested that background levels of 14C-Arg 
incorporation that could be detected in 
“negative” peptide spots of CelluSpots 
arginylation assays upon relatively long 
autoradiographic exposures (e.g., Figs. 3A, 
4B, and 5A; compare with Fig. 2B, right 
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panel) were likely to signify a low but actual 
Ate1-mediated conjugation of 14C-Arg. 
If so, what might be the reason for a 
uniformly low but still detectable (upon 
longer autoradiographic exposures) 
incorporation of 14C-Arg in spots of peptides 
bearing non-canonical N-terminal residues? 
Two mechanistically different and non-
alternative (mutually compatible) 
explanations of background-level 14C-Arg 
incorporation are as follows. In the first 
interpretation, R-transferase might be able to 
conjugate Arg, at a very low, presumably 
physiologically irrelevant efficacy (still 
detectable in 14C-arginylation assays) to at 
least some non-canonical N-terminal 
residues. A different and non-alternative 
interpretation is that background-level 
amounts of 14C-Arg in spots of peptides 
bearing non-canonical N-terminal residues 
reflect the presence, in the corresponding 
peptide spots, of non-zero (but very low) 
admixtures of canonical Nt-arginylatable 
N-terminal residues such as Asp and/or Glu. 
It would be interesting to rigorously 
distinguish between these interpretations by 
carrying out analogous arginylation assays 
with individual (i.e., non-arrayed) short 
peptides that would be synthesized from 
particularly pure amino acid stocks and 
would be purified and authenticated more 
extensively and rigorously than is possible 
with arrays of immobilized peptides. 
Different Ate1 Isoforms Exhibit 
Similar Substrate Preferences – A subset of 
11-residue peptides in our CelluSpots arrays 
was designed to examine the effects of a 
second-position residue on the relative 
efficacy of Ate1-mediated arginylation. 
Peptides of that subset contained N-terminal 
Asp (D). This is a canonical (Nt-
arginylatable) residue and apparently the 
most efficacious acceptor of Arg, among 
N-terminal Asp, Glu or oxidized Cys (Fig. 
1A) (9). N-terminal Asp was followed by a 
varying second-position amino acid residue 
(Xaa), by the Gly-Ser-Gly sequence at 
positions 3-5, and by the sequence (chosen 
quasi-randomly) Phe-Gly-Pro-Ala-Ser-Gly at 
positions 6-11 (Fig. 3 and its legend). In 
addition, the array’s “control” peptide spots 
contained 11-residue peptides of otherwise 
identical sequences but bearing N-terminal 
Arg (R), a non-canonical residue, instead of 
N-terminal Asp (D) (Fig. 3A). The invariant 
sequence Gly-Ser-Gly-Phe-Gly-Pro-Ala-Ser-
Gly at positions 3-11 is not significantly 
similar to sequences in natural mouse 
proteins. Arginylation assays with these 
peptide arrays indicated that all of the above 
peptides, which contained the canonical 
(Nt-arginylatable) N-terminal Asp followed 
by a varying position-2 residue (Xaa) and the 
sequence Gly-Ser-Gly-Phe-Gly-Pro-Ala-Ser-
Gly (positions 3-11), could be arginylated by 
mouse R-transferase, to different but 
significant extents, whereas none of the 
otherwise identical peptides bearing the 
non-canonical N-terminal Arg residue were 
arginylated above background levels (Fig. 3). 
Ate11B7A, Ate11B7B, Ate11A7A, and 
Ate11A7B, the four major splicing-derived 
isoforms of the mouse Ate1 R-transferase, 
differ by the presence or absence of exon 1a 
vs. the sequelogous (similar in sequence 
(106)) exon 1b, and also exon 7a vs. the 
sequelogous exon 7b (Fig. 1D) (3,78,79). 
Carrying out four identical arginylation 
assays with four Ate1 isoforms, we found 
that the relative activities of the purified 
Ate11B7A, Ate11B7B, Ate11A7A, and Ate11A7B 
R-transferases toward the 11-residue peptides 
with N-terminal Asp and a varying residue at 
position 2 were substantially similar (Fig. 3). 
Although one isoform, Ate11A7B, exhibited a 
significantly lower overall arginylation 
activity (per μg of added purified 
R-transferase) than the other three isoforms, 
the substrate preferences of Ate11A7B, 
vis-à-vis the examined set of peptides, were 
substantially similar to those of the other 
three isoforms (Fig. 3; see the legends to 
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Figs. 3-5 for statistical aspects of 14C-Arg 
quantification in these arrays).  
These arginylation assays also 
showed that all four Ate1 isoforms exhibited 
a significant preference for arginylating 
N-terminal Asp-bearing peptides that 
contained either a hydrophobic residue other 
than Trp (specifically, Ala, Val, Leu, Ile, 
Phe, Tyr) or a basic residue (His, Lys, Arg) 
at position 2, in comparison to either acidic 
residues (Asp or Glu) or the Pro residue at 
this position (Fig. 3). Pro and Trp at position 
2 were the least favorable residues at position 
2, in the otherwise identical sequence 
contexts of N-terminal Asp-bearing Asp-
Xaa-Gly-Ser-Gly-Phe-Gly-Pro-Ala-Ser-Gly 
peptides (Fig. 3). It should be noted that the 
isoform Ate11B7B was more sensitive to the 
presence of Asp or Glu at position 2 than the 
other three Ate1 isoforms, a rare instance of a 
specificity difference among Ate1 isoforms 
(Figs. 3 and 4).  
The Overall Charge of a Region 
Adjoining N-terminal Residue Affects the 
Efficacy of Arginylation – All four Ate1 R-
transferase isoforms exhibited significantly 
decreased efficacies of arginylation with 
11-residue peptides in which N-terminal Asp 
was followed by four basic (Arg) residues, in 
comparison to a single Arg at position 2 
(Fig. 4). Three of the four Ate1 isoforms 
were also significantly less efficacious when 
N-terminal Asp was followed by four acidic 
(Asp) residues, in comparison to a single Asp 
at position 2 (Fig. 4). An interesting 
exception was the Ate11A7A isoform, which 
arginylated the N-terminal sequence DDGSG 
comparably to the sequence DDDDD 
(Fig. 4). 
In contrast, a difference in the 
efficacy of arginylation, for all four Ate1 
isoforms, was much smaller between the 
N-terminal sequences DAGSG and DAAAA, 
and the run of four Ala residues after 
N-terminal Asp was even more favorable for 
arginylation than a single Ala at position 2 
(Fig. 5). Notably, even a single position-2 
Asp residue made the resulting peptide a 
significantly less efficacious arginylation 
substrate than the otherwise identical peptide 
in which N-terminal Asp was followed by 
either a single positive (Arg) residue or a 
single small uncharged (Ala) residue (Fig. 4; 
see the legends to Figs. 3-5 for statistical 
aspects of 14C-Arg quantification in these 
arrays). 
Negligible Efficacy of Unoxidized 
N-terminal Cys as a Substrate for 
Arginylation – Earlier studies of conditional 
N-degrons bearing N-terminal Cys have 
shown that the Ate1-mediated 
Nt-arginylation of Cys required its 
preliminary oxidation to Cys-sulfinate or 
Cys-sulfonate (3,4,29). (Although it is a 
priori likely that R-transferase can also 
Nt-arginylate the (less oxidized) N-terminal 
Cys-sulfinate, because its side chain 
“resembles” the side chain of Asp more than 
Cys-sulfonate does, there is no rigorous 
evidence, so far, that bears on this conjecture, 
inasmuch as Cys-sulfinate is readily oxidized 
in vitro to Cys-sulfonate.) In agreement with 
those findings, our results with CelluSpots 
peptide arrays indicated that the unmodified 
N-terminal Cys residue is either a very poor 
arginylation substrate of the Ate1 R-
transferase or not a substrate at all (Fig. 2B, 
right panel, spots C1-C4; Fig. 5A, columns 
5-8, and Fig. 5B, C; see the legends to Figs. 
3-5 for statistical aspects of 14C-Arg 
quantification in these arrays). The latter 
possibility would obtain if the observed, 
essentially background levels of 14C-Arg 
with N-terminal Cys-bearing CelluSpots 
peptides (Fig. 5A, columns 5-8, and Fig. 5B, 
C) resulted from a partial nonenzymatic 
oxidation of Cys in these peptides during 
preparation and handling of CelluSpots 
arrays. 
A small increase over background-
levels of 14C-Arg incorporation could be 
observed with 11-residue peptides bearing 
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unmodified N-terminal Cys when the second 
residue was basic (Lys) (Fig. 5A, columns 
5-8, and Fig. 5B). It remains to be 
determined whether this small effect resulted 
from a weak increase in the otherwise 
negligible activity of R-transferase toward 
unoxidized N-terminal Cys when the second 
residue was basic (Lys) or whether, 
non-alternatively, this effect stemmed from a 
(possibly) increased propensity of N-terminal 
Cys to be slowly and nonenzymatically 
oxidized to Cys-sulfinate and/or 
Cys-sulfonate by oxygen in the air if a 
residue at position 2 was basic. 
Oxidation of N-terminal Cys Allows 
Its Arginylation – To compare Ate1 R-
transferase isoforms by their ability to 
arginylate the unmodified vs. oxidized 
N-terminal Cys residue, we used an 
11-residue peptide whose sequence, 
CKGLAGLPASC, was identical to the 
N-terminal sequence of wild-type mouse 
Rgs4. We also used the otherwise identical 
peptides that differed at position 1 (Fig. 5C). 
Rgs4, a regulator of specific G proteins, has 
been shown to be a conditionally 
Nt-arginylated (and therefore conditionally 
short-lived) physiological substrate of the 
Arg/N-end rule pathway (3,4,29,107). 
N-terminal positions of examined 11-residue 
peptides contained either an unmodified (i.e., 
not deliberately oxidized) N-terminal Cys 
(the same as in wild-type Rgs4) or the 
oxidized N-terminal Cys (Cys-sulfonate), 
which was substituted for unmodified Cys 
during the synthesis of these peptides. Two 
other (control) peptides contained, instead of 
N-terminal Cys, either N-terminal Asp (an 
unconditionally Nt-arginylatable (canonical) 
N-terminal residue; see the Introduction) or 
the 2-residue sequence Arg-Cys, bearing 
N-terminal Arg, a non-canonical residue. The 
latter peptide was a 12-residue one, in 
contrast to 11-residue peptides in the other 
spots, owing to the addition of N-terminal 
Arg (Fig. 5C). 
As expected (given the previous 
evidence about oxidation of N-terminal Cys 
being a prerequisite for its Nt-arginylation 
(3,4,29)), we found that the peptide bearing 
N-terminal Cys-sulfonate (incorporated 
during peptide synthesis) was a significant 
arginylation substrate. In contrast, the 
arginylation, with four examined Ate1 
isoforms, of the otherwise identical peptide 
bearing the unoxidized (more accurately, not 
deliberately oxidized) N-terminal Cys 
residue was at background levels (Fig. 5C, 
column 4 vs. column 3). Also as expected, 
the otherwise identical peptide bearing the 
canonical N-terminal Asp residue (instead of 
Cys) was arginylated much more 
efficaciously than even the oxidized 
N-terminal Cys residue, whereas the 
otherwise identical 12-residue peptide 
bearing the 2-residue N-terminal sequence 
Arg-Cys (N-terminal Arg is a non-canonical 
residue) was not arginylated above 
background levels (Fig. 5C; see also Fig. 2B, 
right panel, spots C1-C4). 
We found that all four examined 
isoforms of the mouse Ate1 R-transferase 
exhibited similar relative efficacies of 
arginylation of peptides in this N-terminal 
Cys-based setting (Fig. 5). These and other 
results of this section disagreed with data of 
an earlier report that some isoforms of Ate1 
are nearly specific for N-terminal Cys (93). 
In particular, none of the four examined Ate1 
isoforms in CelluSpots assays could 
arginylate the unoxidized N-terminal Cys 
residue above background levels of 14C-Arg 
incorporation (Fig. 5). In addition, these Ate1 
isoforms were similar in their relative ability 
to arginylate the oxidized N-terminal Cys 
(Cys-sulfonate) residue (Fig. 5C). 
The Rate of Ate1-dependent Protein 
Degradation Is Influenced by the Overall 
Charge of a Region Adjoining the N-terminus 
– We asked whether the observed influence 
of second-position residues and adjoining 
clusters of charged residues on the efficacy 
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of Nt-arginylation in CelluSpots assays 
(Fig. 4) was also relevant to the rate of 
Ate1-dependent protein degradation. 
Pulse-chase assays were carried out in rabbit 
reticulocyte extract, a previously 
characterized transcription-translation-
degradation system that contains the 
Arg/N-end rule pathway (44,49,73). The 
Arg/N-end rule reporter substrates were 
derivatives of Rgs4, a regulator of G proteins 
that has been identified as an Ate1-dependent 
physiological substrate of the Arg/N-end rule 
pathway (4,29,107). Wild-type mammalian 
Rgs4 proteins bear N-terminal Cys, after the 
cotranslational removal of their N-terminal 
Met by MetAPs. The N-terminal Cys residue 
of Rgs4 has been shown to be oxidized, by 
NO and oxygen, either in vivo or in 
reticulocyte extract to (ultimately) 
Cys-sulfonate, which can be Nt-arginylated 
by the Ate1 R-transferase. The resulting 
Nt-arginylated Rgs4 is processively 
destroyed to short peptides by the 
post-arginylation part of the Arg/N-end rule 
pathway (Fig. 1A) (3,4).  
Degradation assays in reticulocyte 
extract employed the Ub reference technique 
(URT), derived from the Ub fusion technique 
(Fig. 6A) (1,108). In this method, the 
cotranslational cleavage of a URT-based 
protein fusion by deubiquitylases in 
reticulocyte extract produces, at the initially 
equimolar ratio, a test protein with a desired 
N-terminal residue and a “reference” protein, 
in the present case fDHFR-UbK48R, a 
flag-tagged derivative of the mouse 
dihydrofolate reductase (Fig. 6A). In 
URT-based assays, a pulse-labeled test 
protein is quantified by measuring its level 
relative to that of a stable reference protein, 
fDHFR-UbK48R, at each time point of a chase. 
The URT-based, “built-in” reference protein 
increases the accuracy of degradation assays 
(Fig. 6A) (108-110). 
To simplify the mechanics of initial 
targeting, i.e., to bypass the N-terminal 
Cys-oxidation step (it is required for 
degradation of wild-type Rgs4 (3,4,29)), the 
natural N-terminal Cys of Rgs4 was replaced 
by Asp in the context of URT fusion 
(Fig. 6A). In addition, to place an uncharged 
residue at position 2 and to allow changes of 
residues 2-5 without altering the length of the 
reporter, the (charged) Lys residue at position 
2 of wild-type mouse Rgs4 was replaced by 
Ala, and the Gly-Ser-Gly sequence was 
inserted at positions 3-5. As described below, 
the set of constructed and examined Rgs4 
derivatives (Figs. 6 and 7) involved 
alterations of residues at positions 1-5. The 
C-terminally flag-tagged DAGSG-Rgs4f 
(specifically, fDHFR-UbK48R-Asp-Ala-Rgs4f, 
before the cotranslational cleavage, by 
deubiquitylases, at the UbK48R-Asp junction; 
Fig. 6A) (108-110)) was Nt-arginylated by 
Ate1 in reticulocyte extract (Fig. 1A). The 
sequence of the DAGSG-Rgs4f test protein 
was identical to that of wild-type Rgs4, save 
for the replacement of wild-type Cys-Lys by 
Asp-Ala and the insertion of Gly-Ser-Gly. 
In reticulocyte extract, DAGSG-
Rgs4f was rapidly degraded (t1/2 < 10 min; 
Fig. 6B, lanes 5-8, and Fig. 6D). The 
otherwise identical RAGSG-Rgs4f, with the 
N-terminal sequence Arg-Ala, was degraded 
even faster (t1/2 < 1 min; Fig 6B, lanes 1-4, 
and Fig. 6D), most likely because in this case 
the preliminary step of Nt-arginylation was 
neither possible nor necessary prior to the 
recognition of RAGSG-Rgs4f by a 
mammalian N-recognin such as Ubr1 
(Fig. 1A). In contrast, the otherwise identical 
VAGSG-Rgs4f (bearing the N-terminal 
sequence Val-Ala, which is not recognized 
by the Arg/N-end rule pathway) was stable 
during the chase (t1/2 >> 45 min; Fig. 6B, 
lanes 9-12, and Fig. 6D). In addition, the 
initial, time-zero (pre-chase) levels of 
DAGSG-Rgs4f and (particularly) 
RAGSG-Rgs4f were much lower than the 
relative level of VAGSG-Rgs4f, indicating a 
substantial early (pre-chase) degradation of 
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DAGSG-Rgs4f and RAGSG-Rgs4f, but not 
of VAGSG-Rgs4f (Fig. 6B, D). In sum, this 
set of otherwise identical Rgs4-based test 
proteins, which differ solely at their 
N-terminus-proximal positions, is a 
particularly suitable setting for examining 
effects of N-terminal changes on the rate of 
proteolysis by the Arg/N-end rule pathway 
(Fig. 6B, D; see the legends to Figs. 6 and 7 
for statistical aspects of quantifying protein 
degradation in these assays). 
We also compared degradation-rate 
effects of a second-position basic residue 
(Lys) versus either an acidic residue (Asp) or 
an imino residue (Pro) in DXGSG-Rgs4f test 
proteins (X=Asp, Pro, Lys). In agreement 
with a significantly less efficient arginylation 
of N-terminal Asp-bearing CelluSpots 
peptides containing either an acidic (Asp) or 
Pro residue at position 2 (in comparison to a 
basic residue at that position), the 
degradation of DKGSG-Rgs4f, with Lys at 
position 2, was much faster than the 
degradation of either DDGSG-Rgs4f or 
DPGSG-Rgs4f (Fig. 7; see the legends to 
Figs. 6 and 7 for statistical aspects of 
quantifying protein degradation in these 
assays). In sum, the identity of a position-2 
residue, in an N-degron that requires 
Nt-arginylation, can influence the 
degradation rate of a corresponding protein, 
at least in part by altering the rate of 
Nt-arginylation (Fig. 1A). 
We also constructed and examined 
derivatives of DAGSG-Rgs4f that contained 
either one or four Asp residues at positions 
2-5 or, alternatively, either one or four Arg 
residues at the same positions. (These 
changes of Rgs4 were done through 
substitutions of its wild-type residue 2 and of 
the previously inserted Gly-Ser-Gly at 
positions 3-5 (see above) by either four Asp 
or four Arg residues.) Interestingly, 
DDDDD-Rgs4f in which a stretch of four 
acidic (Asp) residues followed N-terminal 
Asp, was found to be long-lived in 
reticulocyte extract (t1/2 >> 45 min; Fig. 6C, 
lanes 13-15, and Fig. 6E), despite the fact 
that N-terminal Asp, when it is present in a 
less disfavorable downstream sequence 
context (e.g., in DAGSG-Rgs4f), is a 
short-lived substrate of the Arg/N-end rule 
pathway (Fig. 6B, lanes 1-4, and Fig. 6D; see 
the legends to Figs. 6 and 7 for statistical 
aspects of quantifying protein degradation in 
these assays). Predictably, the N-terminal 
sequence, Asp-Ala (DA), was a good 
substrate for Nt-arginylation in CelluSpots 
peptide arrays (e.g., Fig. 3A). The absence of 
significant degradation of DDDDD-Rgs4f 
was in qualitative agreement with the relative 
extents of Nt-arginylation of N-terminal Asp 
in the context of CelluSpots peptide arrays, 
in which the N-terminal DDDDD… 
sequence was arginylated much less 
efficaciously than the N-terminal DDGSG… 
sequence (Fig. 4). 
When four basic (Arg) residues 
followed N-terminal Asp, the rate of 
degradation of the resulting DRRRR-Rgs4f 
was nearly identical to that of DR-Rgs4f, 
which contained a single Arg residue after 
N-terminal Asp (followed by the wild-type 
GLA sequence of Rgs4 at positions 3-5) 
(Fig. 6C, lanes 5-8 vs. lanes 1-4, and 
Fig. 6E). These degradation-assay results 
were in qualitative agreement with the 
extents of Nt-arginylation of N-terminal Asp 
in the context of CelluSpots assays, in which 
both the DRGSG… and DRRRR… peptides 
were arginylated, with the DRGSG… peptide 
being a more efficacious Ate1 substrate than 
the DRRRR… peptide (Fig. 4).  
Together, the results of arginylation 
assays on peptide arrays and protein 
degradation assays in reticulocyte extract 
(Figs. 2-7) indicated that multiple acidic 
residues immediately downstream of a 
canonical (arginylatable) N-terminal residue 
such as Asp could significantly attenuate its 
Ate1-mediated Nt-arginylation and, 
consequently, the rate of degradation of a 
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corresponding N-terminal Asp-bearing test 
protein by the Arg/N-end rule pathway. 
While multiple basic residues (Arg) 
downstream of N-terminal Asp also 
decreased the efficacy of Nt-arginylation, 
this decrease was less severe than the one of 
several acidic (Asp) residues, and did not 
strongly influence the rate of degradation of a 
corresponding N-end rule substrate 
(Figs. 4-6). 
Use of CelluSpots Assays to Address 
Reports About Arginylation of Non-
Canonical N-terminal Residues and Specific 
Internal Residues of Cellular Proteins – 
As mentioned in the Abstract and 
Introduction, several publications, over the 
last decade, have suggested, largely on the 
basis of mass spectrometry (MS)-based 
analyses of isolated cellular proteins 
(digested by trypsin or other proteases), that 
the arginylation of specific proteins or their 
natural fragments can involve, to a 
significant extent, non-canonical (non-Asp, 
non-Glu, non-Cys) N-terminal residues, 
including N-terminal Met, Leu, Phe, Val, 
Ala, Thr, Gly, Asn, Lys, and Pro (87-92). In 
addition, a 2005 study described a modified 
13-residue neurotensin hormone that 
appeared to be arginylated, in vivo, at its 
internal Glu-4 residue (96). Neurotensin is 
produced through the processing of a larger 
precursor protein in the endoplasmic 
reticulum (ER) and Golgi. These 
compartments are distinct from the currently 
known locations of the cytosolic/nuclear 
Ate1 R-transferase (96). A subsequent 
publication suggested that Ate1 is capable of 
arginylating not only the α-amino groups of 
N-terminal residues but also γ-carboxyl 
groups of internal (non-N-terminal) Asp and 
Glu in natural proteins, and described several 
proteins, including actin, dystrophin, myosin, 
titin, and tubulin, that appeared to contain, 
according to MS-based data, internal Asp or 
Glu residues conjugated to Arg (94).  
To the best of our knowledge, none of 
the MS-based evidence about significant 
levels of protein arginylation either at 
non-canonical N-terminal residues or at 
specific internal residues (87-92,94-96) has 
been examined, thus far, using independent, 
non-MS methods. We addressed the 
possibility of non-canonical arginylation by 
asking, using C-terminally immobilized 
11-residue CelluSpots peptides and 
14C-arginylation assays, whether specific 
amino acid sequences that encompass the 
previously reported non-canonical 
arginylation sites (87-92,94-96) are capable 
of being significantly arginylated by the 
purified Ate1 R-transferase. 
One set of 14C-arginylation assays 
was carried out with the peptide 
ALYENKPRRPY and its derivatives at 
position 4. The 11-residue sequence 
ALYENKPRRPY is identical to the 
13-residue sequence of mature neurotensin 
(QLYENKPRRPYIL) (96), save for the 
absence of the C-terminal Ile-Leu sequence 
of neurotensin and the presence of 
N-terminal Ala (A), instead of wild-type 
N-terminal Gln (Q), in the 11-residue 
CelluSpots peptide. The Gln→Ala 
N-terminal replacement was necessary owing 
to the possibility of a nonenzymatic 
deamidation of wild-type N-terminal Gln 
(76), as it would yield N-terminal Glu, a 
canonical substrate of Ate1 R-transferase 
(Fig. 1A). The CelluSpots arrays contained 
not only the above 11-residue 
ALYENKPRRPY peptide but also the 
otherwise identical peptides that differed by 
bearing, at position 4, either Asp, Asn, or 
Gln, instead of wild-type Glu (Fig. 8B, 
columns 17-20, and Fig. 8C). The earlier 
MS-based evidence (96) for the in vivo 
arginylation of the neurotensin’s internal 
Glu-4 residue was summarized above. 
We found that none of the 
neurotensin-based peptides (including the 
one containing the wild-type Glu-4 residue) 
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generated a 14C-arginylation signal above 
background levels of CelluSpots assays with 
four individually examined purified Ate1 
R-transferase isoforms, indicating the 
inability of any one among these peptides to 
serve as Ate1 substrates at least in vitro 
(Fig. 8B, columns 17-20, and Fig. 8C, items 
17-20). Given this robustly negative and 
reproducible result, we did not use 
CelluSpots assays to examine analogous 
claims, by another laboratory, about 
arginylation of internal Asp or Glu in actin, 
myosin, and other cellular proteins (94,95). 
To address a related but different set 
of earlier reports about non-canonical 
specificities of Ate1, we carried out 
CelluSpots arginylation assays with eleven 
C-terminally immobilized 11-residue 
peptides (Table 1, entries 53-56 and 74-83) 
whose sequences were identical to the 
N-terminal sequences of some among nearly 
50 proteins that have been previously 
described as in vivo Ate1 substrates that were 
Nt-arginylated at non-canonical (non-Asp, 
non-Glu, non-Cys) N-terminal residues (87). 
In most cases, Nt-arginylation of this kind 
was reported to involve non-canonical 
N-terminal residues of presumed (i.e., neither 
isolated nor otherwise characterized) natural 
protein fragments, generated in vivo by 
unknown proteases (87).  
The putative Nt-arginylation 
substrates listed below were selected from a 
much larger set of claimed non-canonical 
Ate1 substrates (87) to encompass a broad 
range of reported non-canonical N-terminal 
residues, specifically Met, Leu, Pro, Ala, 
Lys, Gly, Asn, Phe, His, and Val. The 
resulting eleven 11-residue peptides were 
identical to the N-terminal sequences of 
either a full-length protein or (presumed) 
protein fragments that have been reported as 
substrates of non-canonical Nt-arginylation 
(87). The CelluSpots arginylation assays with 
these peptides also contained, as items 1 and 
12, a positive (N-terminal Asp-bearing) 
control: 
1. DKGLAGLPASC: the 
Rgs4-derived, 11-residue peptide, a positive 
control. It contains N-terminal Asp, a 
canonical (Nt-arginylatable) residue, and was 
present in the array at two positions, as 
described in Fig. 8A, items 1 and 12, and in 
Fig. 8B, columns 1 and 12. 
2. MCDRKAVIKNA: the light chain 
of cytoplasmic dynein (Dynnl1); 
NP_062656.2. The reported Nt-arginylated 
residue is the initial Met-1 of Dynnl1 (87). 
We note that the N-terminal Met residue, in 
the sequence Met-Cys, is expected to be 
cotranslationally cleaved off, from a nascent 
protein, by Met-aminopeptidases (9). The 
authors of ref. (87), which reported 
Nt-arginylation of the Met-1 residue of the 
full-length Dynnl1, did not mention this 
issue. 
3. LEVLNFFNNQI: a presumed 
fragment of the Ras suppressor protein 1; 
NP_033131.2. The Nt-arginylated residue is 
Leu-65, i.e., the authors (87) reported that 
their protein preparation contained a 
(presumed) fragment of this protein that was 
Nt-arginylated at its N-terminal Leu-65. 
4. PVLCFTQYEES: a presumed 
fragment of the properdin factor 
(complement); NP_032849.1. The 
Nt-arginylated residue is Pro-25, i.e., the 
authors (87) reported that their protein 
preparation contained a (presumed) fragment 
of this protein that was Nt-arginylated at its 
N-terminal Pro-25. 
5. AWGKIGGHGAE: a presumed 
fragment of the hemoglobin alpha-1 chain; 
NP_032244.1. The Nt-arginylated residue is 
Ala-14, i.e., the authors (87) reported that 
their protein preparation contained a 
(presumed) fragment of this protein that was 
Nt-arginylated at its N-terminal Ala-14. 
6. KPVYDELFYTL: a presumed 
fragment of the EH domain containing 
protein Mpast2; AAH12272.1. The 
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arginylated residue is Lys-448, i.e., the 
authors (87) reported that their protein 
preparation contained a (presumed) fragment 
of this protein that was Nt-arginylated at its 
N-terminal Lys-448. 
7. GDDGAEYVVES: a presumed 
fragment of the protein similar to 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH); XP_979290.1. The Nt-
arginylated residue is Gly-43, i.e., the authors 
(87) reported that their protein preparation 
contained a (presumed) fragment of this 
protein that was Nt-arginylated at its 
N-terminal Gly-43. 
8. NSALQCLSNTA: a presumed 
fragment of the ubiquitin-specific protease 4; 
NP_035808.1. The Nt-arginylated residue is 
Asn-314, i.e., the authors (87) reported that 
their protein preparation contained a 
(presumed) fragment of this protein that was 
Nt-arginylated at its N-terminal Asn-314. 
9. FYNELRVAPEE: a presumed 
fragment of β-actin; NP_031419.1. The 
Nt-arginylated residue is Phe-90, i.e., the 
authors (87) reported that their protein 
preparation contained a (presumed) fragment 
of this protein that was Nt-arginylated at its 
N-terminal Phe-90. 
10. HSQAVEELADQ: a presumed 
fragment of the non-muscle myosin Myh9, 
heavy polypeptide 9, isoform 1; 
NP_071855.1. The Nt-arginylated residue is 
His-1194, i.e., the authors (87) reported that 
their protein preparation contained a 
(presumed) fragment of this protein that was 
Nt-arginylated at its N-terminal His-1194. 
11. VLVGDVKDRVA: a presumed 
fragment of the phosphoribosyl 
pyrophosphate synthase-1 (Prps1); 
NP_067438.1. The Nt-arginylated residue is 
Val-206, i.e., the authors (87) reported that 
their protein preparation contained a 
(presumed) fragment of this protein that was 
Nt-arginylated at its N-terminal Val-206.  
12. MDPLNDNIATL: the same 
protein as in item 10 above, but a (presumed) 
different fragment of the non-muscle myosin 
Myh9 (NP_071855.1). The Nt-arginylated 
residue of this fragment is Met-589, i.e., the 
authors (87) reported that their protein 
preparation contained a (presumed) fragment 
of this protein that was Nt-arginylated at its 
N-terminal Met-589. 
We found that ten of these eleven 
CelluSpots peptides, corresponding to 
N-terminal sequences of some among the 
previously reported non-canonical substrates 
of the Ate1 R-transferase (87), generated 
background levels of 14C-Arg incorporation 
with four individually examined purified 
Ate1 isoforms, indicating the inability of 
these peptides to serve as significant Ate1 
substrates at least in vitro (Fig. 8A, items 
2-11, 14, and Fig. 8B, columns 2-11, 14). 
Importantly, the CelluSpots arrays 
containing these 11-residue peptides were 
flanked by spots of the positive-control 
peptide DKGLAGLPASC (item 1 above), 
which contained N-terminal Asp, a canonical 
(Nt-arginylatable) residue. As expected, 
DKGLAGLPASC was efficaciously 
Nt-arginylated by Ate1 isoforms, in striking 
contrast to the absence of significant 
arginylation of the other 11-residue peptides 
(Fig. 8A, items 1, 12, and Fig. 8B, columns 
1, 12; compare with Fig. 8A, items 2-11, 14, 
and with Fig. 8B, columns 2-11, 14). 
Possible causes of very low but detectable 
background-level arginylation in CelluSpots 
peptide arrays, as distinguished from 
negligible (undetectable) levels of 14C-Arg 
incorporation, are discussed in an earlier 
section of Results.  
The single and weak potential 
exception, in which a slightly above-
background level of 14C-Arg incorporation 
was observed with two of the four examined 
Ate1 isoforms, was the peptide 
KPVYDELFYTL, corresponding to the 
(presumed) internal fragment of the Mpast2 
protein (see item 6 above) (Fig. 8A, item 6, 
and Fig. 8B, column 6). The 
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near-background levels of 14C-Arg 
incorporation with the peptide 
KPVYDELFYTL (Fig. 8B, column 6; 
compare with columns 1 and 12) were 
significantly lower, in absolute amounts of 
incorporated 14C-Arg, than the levels of 
14C-Arg vis-à-vis 11-residue peptides bearing 
the unmodified N-terminal Cys residue 
(Fig. 5A, C). As described above, these 
N-terminal Cys-bearing peptides were 
classed as non-arginylatable, in agreement 
with earlier data (4,7,29). 
We also tried to determine whether 
the report about non-canonical 
Nt-arginylation of, for example, the 
N-terminal Met-bearing sequence 
MDPLNDNIATL (87) (see item 12 above) 
could have stemmed from in vivo oxidation 
of N-terminal Met to either Met-sulfoxide or 
Met-sulfone, a change that might have 
converted the non-arginylatable N-terminal 
Met into a possible substrate of Ate1. 
However, we found that the 11-residue 
peptides M(sulfoxide)DPLNDNIATL and 
M(sulfone)DPLNDNIATL were just as 
incapable of arginylation by the four 
individually examined purified Ate1 
isoforms as was the otherwise identical 
unmodified MDPLNDNIATL peptide, 
thereby precluding the above possibility at 
least in vitro (Fig. 2B, right panel, spots 
C6-C8; Fig. 8B, columns 14-16; and Fig. 8C, 
items 14-16). In addition and as expected, the 
12-residue negative-control peptide 
RMDPLNDNIATL, which contained the 
non-canonical N-terminal Arg residue (added 
during peptide synthesis to the 11-residue 
MDPLNDNIATL), also yielded background 
levels of 14C-Arg incorporation in these 
assays (Fig. 2B, right panel, spot C5; 
Fig. 8B, column 13; and Fig. 8C, item 13). 
It was previously suggested that the 
proposed ability of the Ate1 R-transferase to 
arginylate a variety of non-canonical 
N-terminal as well as internal residues in 
cellular proteins may be conferred by 
(unknown) Ate1 cofactors that can be active 
both in vivo and in cell extracts (87,91). If 
correct, this hypothesis may at least partly 
reconcile the direct and extensive 
discrepancy between the cited earlier reports 
(87-92) and our arginylation data with 
peptide arrays and purified Ate1 (Figs. 2-5 
and Fig. 8). Therefore we modified 
CelluSpots arginylation assays by adding an 
extract from mouse cells (the N2a cell line) 
to reaction mixes, either in the absence or the 
presence of the exogenous purified Ate11B7A 
isoform. This modification of arginylation 
assays did not alter any of our findings.  
In particular, CelluSpots 
14C-arginylation assays with extract alone, 
containing only the endogenous Ate1, 
produced arginylation patterns similar to 
those generated in the presence of both the 
extract and the added purified Ate11B7A 
isoform (data not shown). Because the 
absolute levels of 14C-arginylation were 
significantly lower in N2a extract-only 
assays (in the absence of added exogenous 
Ate1), we cannot rule out the possibility that 
procedures for preparing the extract either 
damaged or diluted the postulated (unknown) 
Ate1-modifying factors. With that caveat, 
although explanations of the above 
discrepancy based on the presence, in vivo, of 
(unknown) factors that may alter the 
specificity of Ate1 remain formally possible, 
they were not supported by the above assays. 
Concluding Remarks – In the present 
study, CelluSpots arrays of C-terminally 
immobilized synthetic 11-residue peptides, 
were used, in conjunction with protein 
degradation assays, to analyze the specificity 
of arginylation by purified isoforms of the 
mouse Ate1 R-transferase, a component of 
the Arg/N-end rule pathway (Figs. 1 and 2). 
We showed, among other things, that amino 
acid sequences immediately downstream of a 
substrate’s canonical (Nt-arginylatable) 
N-terminal residue (Asp, Glu or oxidized 
Cys), and particularly a residue at position 2, 
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can affect the rate of Nt-arginylation by 
R-transferase and thereby the rate of 
degradation of a substrate protein (Figs. 3-7). 
Other CelluSpots arginylation assays 
of the present study (Fig. 8) were designed to 
examine specific interpretations of mass 
spectrometry (MS)-based data that have been 
published over the last decade, largely by the 
Kashina laboratory, about the ability of the 
Ate1 R-transferase to arginylate a variety of 
non-canonical (non-Asp, non-Glu, non-Cys) 
N-terminal residues and also specific internal 
(non-N-terminal) Asp or Glu residues in 
many cellular proteins (87-92,94-96). The 
chief reason for concerns about validity of 
the cited reports is a technical one, inasmuch 
as the evidence for non-canonical 
arginylation specificities of Ate1 remained 
almost entirely MS-based (87-92,94-96), 
without a significant attempt, until the 
present study with CelluSpots arrays, to 
examine interpretations of MS data by other, 
independent methods. 
We addressed the 2005 report by the 
Sillard laboratory about arginylation of the 
hormone neurotensin at its internal Glu-4 
residue (96) by carrying our CelluSpots 
arginylation assays using four purified Ate1 
isoforms and 11-residue analogs of the 
13-residue neurotensin. The robustly 
negative results of these arginylation assays 
(Fig. 8B, columns 17-20, and Fig. 8C, items 
17-20) did not contradict the above findings 
(96) directly, given, in particular, the in vitro 
nature of the CelluSpots approach. 
Nevertheless, our results (Fig. 8) do raise 
concerns about the validity of MS-based 
interpretations that suggested the in vivo 
arginylation of internal (as distinguished 
from N-terminal) Asp or Glu residues in a 
number of cellular proteins (94-96). 
In addition and independently, our 
analyses, using CelluSpots arginylation 
assays and four purified Ate1 isoforms, of 
Nt-arginylation of non-canonical N-terminal 
residues encompassed eleven different 
11-residue peptides. These peptides were 
identical to the N-terminal sequences of 
either full-length proteins or (presumed) 
protein fragments that have been reported to 
undergo Nt-arginylation at non-canonical 
N-terminal residues (87). Positive controls, a 
part of CelluSpots arginylation assays, were 
11-residue peptides bearing a canonical 
(Nt-arginylatable) N-terminal residue such as 
Asp (Figs. 2 and 3; Fig. 8A, items 1 and 12; 
and Fig. 8B, columns 1 and 12). As 
described above, the results of these 
arginylation assays were reproducibly and 
robustly negative. Specifically, we observed 
background levels of 14C-arginylation of the 
eleven examined 11-residue peptides (Fig. 8). 
Their sequences were identical to the 
N-terminal sequences of eleven among 
nearly 50 proteins that have been previously 
described as substrates of Ate1 that were 
Nt-arginylated at non-canonical (non-Asp, 
non-Glu, non-Cys) N-terminal residues (87).  
A caveat to the otherwise direct 
contradictions between our findings and 
those in the cited earlier studies is that our 
results were produced in vitro (with purified 
Ate1 R-transferase and peptide arrays), 
whereas most reports about non-canonical 
arginylation of cellular proteins were about 
analyses of natural, in vivo-produced proteins 
(87-92,94-96). Nevertheless, given the clear 
absence of in vitro support for MS-based 
interpretations that suggested significant 
levels of non-canonical arginylation of both 
N-terminal and internal residues in cellular 
proteins, it would be particularly important to 
verify the above interpretations definitively, 
using methods that do not rely on MS alone. 
 
Experimental Procedures 
 
Plasmids, cDNAs, and Primers – The 
NEB Turbo E. coli strain (New England 
Biolabs (NEB), Ipswich, MA) was used for 
cloning and maintaining plasmids. Phusion 
High-Fidelity DNA polymerase (NEB) was 
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used for PCR. All constructed plasmids 
(Table 2) were verified by DNA sequencing. 
pKP496, the parental plasmid used for 
constructing Ub reference technique 
(URT)-based plasmids, has been described 
previously (44). 
Purification of Mouse Ate1 R-
transferase from E. coli – The plasmids 
pCB407 (Ate11B7A), pCB408 (Ate11B7B), 
pCB409 (Ate11A7A), and pCB410 (Ate11A7B) 
(Table 2) expressed isoform-specific (Fig. 
1C) mouse His10-Ub Ate1 fusions that could 
be purified and deubiquitylated in vitro using 
a previously described technique (111).  
1-liter cultures of BL21 (DE2) E. coli 
transformed with one of the above plasmids 
were grown to an A600 of ~0.6 at 37°C in 
Luria Broth (LB) containing 50 μg/ml 
ampicillin. Cultures were cooled on ice for 
45 min, then induced by the addition of 
isopropyl-β-D-thiogalactoside (IPTG) to the 
final concentration of 0.25 mM for 6 h at 
room temperature. Cells were harvested by 
centrifugation at 2,000g for 10 min at 4°C. 
Pelleted cells were resuspended in 15 ml 
PBS containing 30% (vol/vol) glycerol, 
0.3 M NaCl, 12 mM imidazole, 20 mM 
β-mercaptoethanol, and 1 mg/mL lysozyme, 
followed by freezing in liquid nitrogen. 
Samples were then thawed slowly on ice and 
centrifuged at 27,000g for 30 min at 4°C. 
The N-terminal His10-Ub fusions of Ate1 
isoforms were then purified by Ni-NTA 
chromatography, with elution by 0.3 M 
imidazole. Eluted proteins were dialyzed 
overnight against 5% (vol/vol) glycerol, 
0.3 M NaCl, 2 mM β-mercaptoethanol, and 
50 mM Na2HPO4-NaH2PO4 (pH 8.0), 
containing 1X Complete EDTA-free protease 
inhibitor cocktail (Roche). The N-terminal 
His10-Ub moiety was cleaved off by 
incubating dialyzed samples for 1 h at 37°C 
with purified Usp2cc deubiquitylase (111). 
The latter was added at the 1:10 molar ratio. 
The resulting samples were dialyzed against 
5% (vol/vol) glycerol, 0.15 M NaCl, 10 mM 
β-mercaptoethanol, 50 mM Tris (pH 7.4), 
followed by further purification of 
(deubiquitylated) Ate1 using Mono-S 
chromatography (Pharmacia Biotech: Id 
#9723125), with an elution gradient between 
0.15 M and 1 M NaCl in the above dialysis 
buffer. Peak Ate1 fractions were pooled, 
dialyzed overnight at 4°C against 30% 
(vol/vol) glycerol, 0.15 M NaCl, 10 mM 
β-mercaptoethanol, and 50 mM Tris-HCl 
(pH 7.4), and stored at -80°C. 
CelluSpots-Based Arginylation 
Assays – CelluSpots™ peptide arrays spotted 
on glass slides were synthesized by Intavis 
(Köln, Germany). Each slide contained two 
side-by-side identical copies of the array 
(Fig. 2A, B). Mouse Ate1-dependent 
arginylation assays were performed as 
described previously (79), with slight 
modifications. Individual (rectangular) 
peptide arrays were “outlined” with 
ImmEdge hydrophobic barrier pen (Vector 
Labs, Burlingame, CA) to minimize the 
required reaction volume. 90-μl reactions 
samples containing 5.8 μM 14C-Arg (Perkin 
Elmer NEC267E050UC; 346 mCi/mmol), 
purified total E. coli tRNA (0.6 mg/mL), and 
E. coli aminoacyl-tRNA synthetases (800 
U/mL; Sigma-Aldrich) in 5 mM ATP, 
0.15 M KCl, 10 mM MgCl2, 1 mM 
dithiothreitol (DTT), 50 mM Tris-HCl 
(pH 8.0) were preincubated at 37°C for 15 
min to allow the formation of Arg-tRNA. 
Thereafter a specific purified Ate1 isoform 
(2 μg) was added, and the resulting mixtures 
(final volumes of 0.1 ml) were added to each 
array. Arginylation was allowed to proceed 
for 1 h at 37°C in a humidified chamber with 
gentle rocking. Reactions were quenched by 
rinsing the arrays twice with a large volume 
excess (10 ml) of Tris-Buffered Saline (TBS) 
(1.15 M NaCl, 50 mM Tris-HCl, pH 7.5) 
containing, in addition, 1% Tween-20 and 
RNase A (10 μg/μl). Arrays were then 
washed 3 times for 20 min each in the same 
buffer (including RNase A) at 37°C, 
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followed by an overnight (~16 h) wash, at 
room temperature, in TBS containing 
1% Tween-20 but no RNase A. The resulting 
slides were washed once with 10 mM Tris, 
pH 7.5, and were allowed to air-dry, 
followed by autoradiography for varying 
times (usually ~2 weeks), using a 
PhosphorImager-type screen. The exposed 
screens were scanned using a Storm-860 
Scanner (Molecular Dynamics, Caesarea, 
Israel). Quantification of 14C spot intensities 
was performed using the array analysis 
module of ImageQuant TL software (GE 
Healthcare, Little Chalfont, UK).  
In Vitro Transcription-Translation-
Degradation Assays – The TNT T7 Coupled 
Transcription/Translation System (Promega, 
Madison, WI) was used to carry out 
transcription-translation-degradation assays, 
largely as described previously (44,50,73) 
(see also http://www.tanseylab.com/the-myc-
family-of-oncoprote/ultimate-mammal-
denatip.pdf). Nascent proteins in reticulocyte 
extract were pulse-labeled with L-
[35S]methionine (0.55 mCi/ml, 
1,000 Ci/mmol; MP Biomedicals, Santa Ana, 
CA) for 10 min at 30°C in the total volume 
of 30 μl. The labeling was quenched by the 
addition of cycloheximide and unlabeled 
methionine to the final concentrations of 
0.1 mg/ml and 5 mM, respectively, bringing 
the total volume to 40 μl. Samples of 10 μl 
were removed at indicated time points. The 
reaction was immediately terminated by the 
addition of 80 μl of TSD buffer (1% SDS, 
5 mM DTT, 50 mM Tris-HCl, pH 7.4), a 
sample was snap-frozen in liquid nitrogen, 
and was stored at -80°C until further 
processing, which comprised heating the 
samples at 95°C for 10 min, followed by 
dilution with 1 ml of TNN buffer (0.5% 
NP40, 0.25 M NaCl, 5 mM Na-EDTA, 
50 mM Tris-HCl, pH 7.4) containing 1x 
Complete Protease Inhibitor Cocktail (Roche 
Diagnostics, Indianapolis, IN). Samples were 
thereafter immunoprecipitated using 10 μl of 
anti-FLAG M2 magnetic beads (Sigma-
Aldrich), with rocking at 4°C for 4 h, 
followed by four washes in TNN buffer, 
resuspension in 20 μl of SDS-sample buffer, 
and heating at 95°C for 10 min. 
Immunoprecipitated proteins were 
fractionated by SDS 4–15% PAGE, followed 
by autoradiography. Quantification of 
autoradiograms was carried out using Storm 
860 Scanner (Molecular Dynamics).  
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The abbreviations used 
MS, mass spectrometry; Nt, N-terminal; R-transferase, arginyltransferase or 
Arg-tRNA-protein transferase; N-degron, an N-terminal degradation signal recognized by the 
N-end rule pathway; N-recognin, an E3 ubiquitin ligase that can recognize at least some 
N-degrons; Ub, ubiquitin. 
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Figure Legends 
 
FIGURE 1. The mammalian N-end rule pathway and isoforms of the mouse 
Ate1 R-transferase.  
See the Introduction for references and descriptions of the pathway’s mechanistic aspects 
and functions. Amino acid residues are denoted by single-letter abbreviations. A yellow oval 
denotes the rest of a protein substrate.  
A, the mammalian Arg/N-end rule pathway. It targets proteins for degradation through 
their specific unacetylated N-terminal residues. “Primary”, “secondary”, and “tertiary” refer to 
mechanistically distinct classes of destabilizing N-terminal residues. Ntan1 and Ntaq1 are 
N-terminal amidases (Nt-amidases) that convert, respectively, the tertiary destabilizing N-terminal 
residues Asn and Gln to Asp and Glu. The Ate1 R-transferase (arginyltransferase or 
Arg-tRNA-protein transferase) conjugates Arg, a primary destabilizing residue, to N-terminal Asp, 
Glu and (oxidized) Cys (the “canonical” N-terminal residues). “Type 1” and “type 2” refer, 
respectively, to two sets of primary destabilizing N-terminal residues, basic (Arg, Lys, His) and 
bulky hydrophobic (Leu, Phe, Trp, Tyr, Ile, and also Met, if the latter is followed by a bulky 
hydrophobic residue (Ф)). These sets of N-terminal residues are recognized by two distinct 
substrate-binding sites of N-recognins, the pathway’s E3 ubiquitin ligases Ubr1, Ubr2, Ubr4, and 
Ubr5.  
B, the mammalian Ac/N-end rule pathway. It targets proteins through their Nα-terminally 
acetylated (Nt-acetylated) residues. Red arrow on the left indicates the cotranslational removal of 
the N-terminal Met residue by Met-aminopeptidases (MetAPs). N-terminal Met is retained if a 
residue at position 2 is larger than Val. See the Introduction for references and additional aspects 
of the Ac/N-end rule pathway.  
C, the exons, including alternative exons (1A/1B and 7A/7B) of the mouse Ate1 gene, 
which encodes isoforms of R-transferase. The deduced lengths (in amino acid residues) of the 
encoded Ate1 exons are indicated on top. D, Mouse R-transferase isoforms that are produced 
through alternative splicing of Ate1 pre-mRNA. The terminology of these isoforms (Ate11A7A, 
Ate11A7B, Ate11B7A, Ate11B7B, Ate11A7AB, Ate11B7AB) (9,79) is based on the presence or absence of 
the alternative exons 1A/1B and 7A/7B. Ate11A7AB and Ate11B7AB are minor isoforms that result 
from the retention of both variants of exon 7 (79). 
 
FIGURE 2. Design and validation of CelluSpots arginylation assays.  
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A, Layout of two virtually identical copies of a CelluSpots 96-spot array of C-terminally 
immobilized 11-residue synthetic peptides that are produced and spotted onto coated microscope 
slides (102). Each peptide spot is denoted by a letter (A-D) and a number (1-24). For the complete 
sequences of these 96 peptides, see Table 1. For the five N-terminal residues of these 11-residue 
peptides, see the lower part of panel B. Each individual CelluSpots array (left panel vs. right 
panel) was “bounded” through the use of a hydrophobic pen, making it possible for two arrays on 
a slide to be used for two separate enzymatic reactions. 
B, rectangle on the left: arginylation assay was carried out with a CelluSpots peptide array 
containing a complete reaction mix (including 14C-Arg; see Experimental Procedures) save for the 
absence of Ate1 R-transferase. Note negligible (essentially undetectable) levels of 14C-Arg 
incorporation under these conditions.  
B, rectangle on the right: the otherwise identical assay was carried out in the presence of 
purified mouse Ate11B7A R-transferase. Note that “negative” peptide spots, containing 11-residue 
peptides bearing non-canonical (non-Asp, non-Glu, non-Cys) N-terminal residues, exhibited 
negligible (undetectable) levels of 14C-Arg incorporation at this level of autoradiographic 
exposure. Significantly longer autoradiographic exposures made background levels of 14C-Arg 
incorporation detectable in the presence of Ate1 but still negligible (undetectable) in the absence 
of Ate1 (left panel). See Results for possible causes of very low but detectable background-level 
14C-Arg incorporation in spots of peptides bearing non-canonical N-terminal residues. The lower 
part of panel B recapitulates the arrangement of 96 peptide spots in a rectangle of panel A, and in 
addition cites the first five residues of each 11-residue peptide. Spot numbers are in green. The 
canonical (Nt-arginylatable) N-terminal residues Asp, Glu, and Cys (the latter a precursor of 
Nt-arginylatable oxidized Cys) are in red. Table 1 cites complete sequences of 11-residue 
peptides. (Two peptides, at C1 and C5, were 12 residues long.) 
 
FIGURE 3. Effect of an amino acid residue at position 2 on the arginylation 
activity of R-transferase.  
A, 14C-Arg autoradiograms of CelluSpots arginylation assays with the four purified Ate1 
R-transferase isoforms, Ate11A7A, Ate11A7B, Ate11B7A, and Ate11B7B, and with 11-residue peptides 
XZGSGFGPASG (X=D, R; Z=G, A, S, T, C, V, L, I, M, P, Y, W, D, E, N, Q, H, K, R). Identical 
assays were carried out, separately, with Ate11A7A, Ate11A7B, Ate11B7A, and Ate11B7B. 
B, Quantification of results in A, using 14C-Arg autoradiography and normalizing the level 
of arginylation to arginylation of the N-terminal Asp-Gly (DG)-bearing 11-residue peptide. This 
quantification, in the present figure and in Figs. 4C and 5B, involved subtraction of the 
background level of 14C-Arg, a single value for a given peptide array, defined by spots with lowest 
levels of 14C-Arg. This and other arginylation assays (Figs. 4 and 5A, B) were carried out, 
independently, at least two times, and yielded results within 10% of the data shown in B. 
 
FIGURE 4. Influence of charge clusters adjoining the N-terminal residue on 
the rate of arginylation of CelluSpots peptides. 
A, Complete sequences of the examined 11-residue peptides. The N-terminal Asp (D) 
residue, in a subset of peptides, is in red. 
B, 14C-Arg autoradiograms of CelluSpots arginylation assays with the four purified Ate1 
R-transferase isoforms, Ate11A7A, Ate11A7B, Ate11B7A, and Ate11B7B, and with the 11-residue 
peptides shown in A. 
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C, Quantification of results in B, using 14C-Arg autoradiography and normalizing the level 
of arginylation to arginylation of the Asp-Ala-bearing 11-residue peptide (DA1). These and other 
quantified arginylation assays (Figs. 3 and 5A, B) were carried out, independently, at least two 
times, and yielded results within 10% of the data shown in B. 
 
FIGURE 5. Examination of the relative efficacy of arginylation of the 
unmodified N-terminal Cys and a varying residue at position 2. 
A, 14C-Arg autoradiograms of CelluSpots arginylation assays with the four purified Ate1 
R-transferase isoforms, Ate11A7A, Ate11A7B, Ate11B7A, and Ate11B7B, and with the 11-residue 
peptides XZGSGFGPASG (X=D, C, E; Z=S, D, K, P). 
B, Quantification of results in B, using 14C-Arg autoradiography, and normalizing the level 
of Nt-arginylation to Nt-arginylation of the Asp-Ser-bearing 11-residue peptide. These and other 
quantified arginylation assays (Figs. 3 and 4) were carried out, independently, at least two times, 
and yielded results within 10% of the data shown in B. 
C, 14C-Arg autoradiograms of CelluSpots arginylation assays with the four purified Ate1 
R-transferase isoforms, Ate11A7A, Ate11A7B, Ate11B7A, and Ate11B7B, and with the 11-residue 
peptides XKGLAGLPASC (X=RC, D, C, and Cys-sulfonate). The sequence CKGLAGLPASC is 
the N-terminal sequence of mouse Rgs4 (see Results). 
 
FIGURE 6. Pulse-chase degradation assays using Rgs4-based Arg/N-end rule 
substrates and the ubiquitin reference technique. 
A, The ubiquitin reference technique (URT). For its description and references, see Results. 
B, 35S-pulse-chase analyses, in rabbit reticulocyte extract, of XZGSG-Rgs4 (X=R, D, V; 
Z=A), a set of mouse Rgs4-based test proteins. Rgs4 is a regulator of G proteins and a 
conditionally short-lived physiological substrate of the Arg/N-end rule pathway (see Results for 
references and additional information). In these test proteins, the sequence Gly-Ser-Gly (GSG) 
was inserted at positions 3-5, to make possible its replacements, in test proteins of panel C, with 
the sequences RRR or DDD (see below). C-terminally flag-tagged XZGSG-Rgs4f proteins were 
coexpressed, in reticulocyte extract, with the N-terminally flag-tagged fDHFR-Ub reference 
protein, initially as a single Ub fusion (see panel A), and were labeled for 10 min at 30°C with 
35S-Met/Cys, followed by a chase for 45 min, immunoprecipitation with anti-flag antibody, 
SDS-PAGE of immunoprecipitated proteins, and autoradiography. The bands of 35S-labeled 
XZ-Rgs4f and 
fDHFR-Ub are shown on the left. Lanes 1-4, RAGSG-Rgs4f. Lanes 5-8, 
DAGSG-Rgs4f. Lanes 9-12, VAGSG-Rgs4f. 
C, Same as in B, but with XZ-Rgs4f (X=D, R; Z=R, RRRR, D, DDDD) test proteins, in 
some of which the sequences RRR or DDD replaced the sequence GSG at positions 3-5 (see 
above and Results). Lanes 1-4, DRGSG-Rgs4f. Lanes 5-8, DRRRR-Rgs4f (denoted as 
DR4-Rgs4f). Lanes 9-12, DDGSG-Rgs4f. Lanes 13-16, DDDDD-Rgs4f (denoted as DD4-Rgs4f). 
D, Quantification of data in B.  
E, Quantification of data in C. These and other quantified pulse-chases (Fig. 7) were 
carried out, independently, at least three times, and yielded results within 10% of the data values 
shown in D and E. 
 
FIGURE 7. Efficacy of N-terminal arginylation and its influence on the 
degradation rate of Arg/N-end rule substrates. 
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A, The ubiquitin reference technique (URT) (see Fig. 6A and Results) and 35S-pulse-chases 
in reticulocyte extract were used to examine the arginylation-dependent degradation of the 
DZ-Rgs4f test proteins (Z=D, K, P) (in the presence of the 
fDHFR-Ub reference protein) by the 
Arg/N-end rule pathway. The bands of 35S-labeled DZ-Rgs4f and 
fDHFR-Ub are shown on the 
left. Lanes 1-4, DD-Rgs4f. Lanes 5-8, DK-Rgs4f. Lanes 9-12, DP-Rgs4f. As shown in Figs. 3 and 
5A, B, the relative efficacy of Nt-arginylation of N-terminal Asp is a function of the identity of a 
residue at position 2 (see also Results). 
B, Quantification of data in A. These and other quantified pulse-chases (Fig. 6) were 
carried out, independently, at least three times, and yielded results within 10% of the data values 
shown in A. 
 
 
 
FIGURE 8. Use of CelluSpots assays to address reports about arginylation of 
non-canonical N-terminal residues and specific internal residues of cellular 
proteins. 
A, The list of 11-residue CelluSpots peptides whose sequences were identical to the 
N-terminal sequences of either a full-length protein (item 2) or presumed natural fragments of 
other proteins (items 3-11) that have been reported to be Nt-arginylated by Ate1 at their 
non-canonical (non-Asp, non-Glu, non-Cys) N-terminal residues (87-92). See Results for a 
detailed list of these peptides, which contains additional information and relevant references. Items 
1 and 12 refer to a positive-control peptide that contained N-terminal Asp, a canonical 
(Nt-arginylatable) residue.  
B, 14C-Arg autoradiograms of CelluSpots arginylation assays with the four purified Ate1 
R-transferase isoforms, Ate11A7A, Ate11A7B, Ate11B7A, and Ate11B7B, and with twenty peptides 
shown in panels A (items 1-12) and C (items 13-20). Column 1, the positive-control peptide 
bearing the canonical (Nt-arginylated) N-terminal Asp residue (see item 1 in A). Columns 2-11, 
the sequences of these peptides are shown, respectively, in items 2-11 in A. Column 12, the same 
positive-control peptide (bearing the canonical N-terminal Asp residue) that was also present in 
peptide spots of column 1 (see item 1 in A). Columns 13-16, the sequences of these peptides 
shown in items 13-16 in C. Column 17, the peptide shown in item 17 in C. The sequence of this 
peptide, ALYENKPRRPY, was identical to the 13-residue sequence of the mature neurotensin 
hormone (QLYENKPRRPYIL) (96), save for the absence of the C-terminal Ile-Leu sequence of 
neurotensin and the presence of N-terminal Ala (A), instead of wild-type N-terminal Gln (Q). 
A fraction of the QLYENKPRRPYIL neurotensin was reported to be arginylated at its internal 
Glu-4 residue (96). Hence the use of CelluSpots arginylation assays and the four purified isoforms 
of the Ate1 R-transferase with ALYENKPRRPY, a close analog of the 13-residue neurotensin, to 
determine whether the reported in vivo arginylation of neurotensin at the internal Glu-4 residue  
(96) could be observed in vitro as well. Columns 18-20, the sequences of these peptides are 
shown, respectively, in items 18-20 in C.  
C, Items 13-20 are the continuation of the list of CelluSpots peptides in panel A that have 
been examined, as indicated in B, for the extent of their non-canonical arginylation in CelluSpots 
assays. 
Note background levels of 14C-Arg incorporation with all of the examined peptides 
(columns 2-11 and 13-20), save for the (expected) efficacious arginylation of a positive-control 
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peptide (see items 1 and 12 in A and columns 1 and 12 in B). See the last section of Results for 
additional details. 
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Table 1. Location and complete sequences of CelluSpots array peptides (Fig. 2). 
 
 Spot Sequence Name N-term. 
1 A 1 DGGSGFGPASG DG-GSG amine 
2 A 2 DAGSGFGPASG DA-GSG amine 
3 A 3 DSGSGFGPASG DS-GSG amine 
4 A 4 DTGSGFGPASG DT-GSG amine 
5 A 5 DCGSGFGPASG DC-GSG amine 
6 A 6 DVGSGFGPASG DV-GSG amine 
7 A 7 DLGSGFGPASG DL-GSG amine 
8 A 8 DIGSGFGPASG DI-GSGS amine 
9 A 9 DMGSGFGPASG DM-GSG amine 
10 A10 DPGSGFGPASG DP-GSG amine 
11 A11 DFGSGFGPASG DF-GSG amine 
12 A12 DYGSGFGPASG DY-GSG amine 
13 A13 RGGSGFGPASG RG-GSG amine 
14 A14 RAGSGFGPASG RA-GSG amine 
15 A15 RSGSGFGPASG RS-GSG amine 
16 A16 RTGSGFGPASG RT-GSG amine 
17 A17 RCGSGFGPASG RC-GSG amine 
18 A18 RVGSGFGPASG RV-GSG amine 
19 A19 RLGSGFGPASG RL-GSG amine 
20 A20 RIGSGFGPASG RI-GSG amine 
21 A21 RMGSGFGPASG RM-GSG amine 
22 A22 RPGSGFGPASG RP-GSG amine 
23 A23 RFGSGFGPASG RF-GSG amine 
24 A24 RYGSGFGPASG RY-GSG amine 
25 B 1 DWGSGFGPASG DW-GSG amine 
26 B 2 DDGSGFGPASG DD-GSG amine 
27 B 3 DEGSGFGPASG DE-GSG amine 
28 B 4 DNGSGFGPASG DN-GSG amine 
29 B 5 DQGSGFGPASG DQ-GSG amine 
30 B 6 DHGSGFGPASG DH-GSG amine 
31 B 7 DKGSGFGPASG DK-GSG amine 
32 B 8 DRGSGFGPASG DR-GSG amine 
33 B 9 DGPSGFGPASG DGP3-GSG amine 
34 B10 DGGPGFGPASG DGP4-GSG amine 
35 B11 DGGSPFGPASG DGP5-GSG amine 
36 B12 DGGSGPGPASG DGP6-GSG amine 
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37 B13 RWGSGFGPASG RW-GSGS amine 
38 B14 RDGSGFGPASG RD-GSGS amine 
39 B15 REGSGFGPASG RE-GSGS amine 
40 B16 RNGSGFGPASG RN-GSGS amine 
41 B17 RQGSGFGPASG RQ-GSGS amine 
42 B18 RHGSGFGPASG RH-GSGS amine 
43 B19 RKGSGFGPASG RK-GSGS amine 
44 B20 RRGSGFGPASG RR-GSGS amine 
45 B21 RGPSGFGPASG RGP3-GSG amine 
46 B22 RGGPGFGPASG RGP4-GSG amine 
47 B23 RGGSPFGPASG RGP5-GSG amine 
48 B24 RGGSGPGPASG RGP6-GSG amine 
49 C 1 RCKGLAGLPASC Rgs4 Arg amine 
50 C 2 DKGLAGLPASC Rgs4 C2D amine 
51 C 3 CKGLAGLPASC Rgs4  amine 
52 C 4 C(sulfonate)KGLAGLPASC Rgs4, N-terminal Cys-sulfonate. amine 
53 C 5 RMDPLNDNIATL Myh9, Arg amine 
54 C 6 MDPLNDNIATL Myh9  amine 
55 C 7 M(sulfoxide)DPLNDNIATL Myh9, Met(sulfoxide) amine 
56 C 8 M(sulfone)DPLNDNIATL Myh9, Met(sulfone) amine 
57 C 9 ALYENKPRRPY NT1-11, Q1A acetyl 
58 C10 ALYDNKPRRPY NT1-11, Q1A, E4D acetyl 
59 C11 ALYNNKPRRPY NT1-11, Q1A, E4N acetyl 
60 C12 ALYQNKPRRPY NT1-11, Q1A, E4Q acetyl 
61 C13 DSGSGFGPASG GSG, G1D amine 
62 C14 DDGSGFGPASG GSG, G1D,A2D amine 
63 C15 DKGSGFGPASG GSG, G1D,A2K amine 
64 C16 DPGSGFGPASG GSG, G1D,A2P amine 
65 C17 CSGSGFGPASG GSG, G1C amine 
66 C18 CDGSGFGPASG GSG, G1C,A2D amine 
67 C19 CKGSGFGPASG GSG, G1C,A2K amine 
68 C20 CPGSGFGPASG GSG, G1C,A2P amine 
69 C21 ESGSGFGPASG GSG, G1C amine 
70 C22 EDGSGFGPASG GSG, G1E,A2D amine 
71 C23 EKGSGFGPASG GSG, G1E,A2K amine 
72 C24 EPGSGFGPASG GSG, G1E,A2P amine 
73 D 1 DKGLAGLPASC Rgs4, C2D amine 
74 D 2 MCDRKAVIKNA dynein, cytoplasmic, light peptide amine 
75 D 3 LEVLNFFNNQI Ras suppressor protein 1  amine 
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76 D 4 PVLCFTQYEES Properdin factor (complement) amine 
77 D 5 AWGKIGGHGAE hemoglobin alpha 1 chain amine 
78 D 6 KPVYDELFYTL Mpast2, an EH domain containing 
protein  
amine 
79 D 7 GDDGAEYVVES similar to GAPDH amine 
80 D 8 NSALQCLSNTA Ubiquitin-specific protease 4 amine 
81 D 9 FYNELRVAPEE beta-actin amine 
82 D10 HSQAVEELADQ myosin, heavy polypeptide 9, non-
muscle isoform 
amine 
83 D11 VLVGDVKDRVA phosphoribosyl pyrophosphate synthase 
1 (Prps1) 
amine 
84 D12 DKGLAGLPASC Rgs4, C2D amine 
85 D13 DRGSGFGPASG DR1-GSG amine 
86 D14 DRRRRFGPASG DR4-GSG amine 
87 D15 RRGSGFGPASG RR1-GSG amine 
88 D16 RRRRRFGPASG RR4-GSG amine 
89 D17 DDGSGFGPASG DD1-GSG amine 
90 D18 DDDDDFGPASG DD4-GSG amine 
91 D19 RDGSGFGPASG RD1-GSG amine 
92 D20 RDDDDFGPASG RD4-GSG amine 
93 D21 DAGSGFGPASG DA1-GSG amine 
94 D22 DAAAAFGPASG DA4-GSG amine 
95 D23 RAGSGFGPASG RA1-GSG amine 
96 D24 RAAAAFGPASG RA4-GSG amine 
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Table 2. Plasmids used in this study. 
Plasmid Description Source or Reference 
pcDNA3 
AmpR ; NeoR ; Expression vector for cloning your 
gene of interest  
Invitrogen 
pH10UE  
AmpR , pET15b-based vector with 10His-Ub fusion 
cassette 
(111) 
pKP496 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha Ub-MCS-flag under the control of 
CMV promoter. MCS has SacII, EcoRI, XhoI, ClaI 
and EcoRV unique cloning sites 
(43) 
pBW359 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-DRGSG-Gly3mRgs4-flag under 
the control of CMV promoter  
This study 
pBW360 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-DRRRR-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pBW361 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-DDGSG-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pBW362 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-DDDDD-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pBW363 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-DAGSG-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pBW364 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-DAAAA-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pBW365 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-RAGSG-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pBW363 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-VAGSG-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pBW367 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-DSGSG-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pBW368 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-DKGSG-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pBW369 
AmpR ; NeoR ; pcDNA3.0-based plasmid encoding 
flag-DHFR-ha-Ub-DPGSG-Gly3mRgs4-flag under 
the control of CMV promoter 
This study 
pCB407 
AmpR ; pH10UE-based vector used for the bacterial 
expression of a fusion between His10-ubiquitin and 
(81) 
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Ate11B7A 
pCB408 
AmpR ; pH10UE-based vector used for the bacterial 
expression of a fusion between His10-ubiquitin and 
Ate11B7B 
(81) 
pCB409 
AmpR ; pH10UE-based vector used for the bacterial 
expression of a fusion between His10-ubiquitin and 
Ate11A7A 
(81) 
pCB410 
AmpR ; pH10UE-based vector used for the bacterial 
expression of a fusion between His10-ubiquitin and 
Ate11A7B 
(81) 
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A+ Ate1- Ate1
A1 A12A11A10A9A8A7A6A5A3A2 A4
A13 A24A23A22A21A20A19A18A17A15A14 A16
B1 B12B11B10B9B8B7B6B5B3B2 B4
B13 B24B23B22B21B20B19B18B17B15B14 B16
C1 C12C11C10C9C8C7C6C5C3C2 C4
C13 C24C23C22C21C20C19C18C17C15C14 C16
D1 D12D11D10D9D8D7D6D5D3D2 D4
D13 D24D23D22D21D20D19D18D17D15D14 D16
A1 A12A11A10A9A8A7A6A5A3A2 A4
A13 A24A23A22A21A20A19A18A17A15A14 A16
B1 B12B11B10B9B8B7B6B5B3B2 B4
B13 B24B23B22B21B20B19B18B17B15B14 B16
C1 C12C11C10C9C8C7C6C5C3C2 C4
C13 C24C23C22C21C20C19C18C17C15C14 C16
D1 D12D11D10D9D8D7D6D5D3D2 D4
D13 D24D23D22D21D20D19D18D17D15D14 D16
A1: DGGSG-
A11: DFGSG-A10: DPGSG-A9: DMGSG-A8: DIGSG-A7: DLGSG-
A6: DVGSG-A5: DCGSG-A4: DTGSG-A3: DSGSG-   A2: DAGSG-
A12: DYGSG-
A13-A24: as in A1-12, but with Arg (R) instead of Asp (D) at position 1.
B1: DWGSG-
B11: DGGSP-B10: DGGPG-B9: DGPSG-B8: DRGSG-B7: DKGSG-
B6: DHGSG-B5: DQGSG-B4: DNGSG-B3: DEGSG-   B2: DDGSG-
B12: DGGSG-
C11: ALYNN-C10: ALYDN-C9: ALYEN-C8: M*DPLN-C7: M**DPLN- C12: ALYQN-
A
B
C
D
B13-B24: as in B1-12, but with Arg (R) instead of Asp (D) at position 1.
C13: DSGSG-
C23: EKGSG-C22: EDGSG-C21: ESGSG-C20: MPGSG-C19: CKGSG-
C18: CDGSG-C17: CSGSG-C16: DPGSG-C15: DKGSG-   C14: DDGSG-
C24: EPGSG-
D1: DKGLA-
D11: VLVGD-D10: HSQAV-D9: FYNEL-D8: NSALQ-D7: GDDGA-
D6: KPVYD-D5: AWGKI-D4: PVLCF-D3: LEVLN-   D2: MCDRK-
D12: DKGLA-
D13: DRGSG-
D23: RAGSG-D22: DAAAA-D21: DAGSG-D20: RDDDD-D19: RDGSG-
D18: DDDDD-D17: DDGSG-D16: RRRRR-D15: RRGSG-   D14: DRRRR-
D24: RAAAA-
Fig. 2, Wadas et al.
C1: RCKGL- C6: MDPLN-C5: RMDPL-C4: C*KGLA-C3: CKGLA-   C2: DKGLA-
B
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Fig. 3, Wadas et al.
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Fig. 4, Wadas et al.
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Fig. 5, Wadas et al.
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Fig. 6, Wadas et al.
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Fig. 7, Wadas et al.
A
B
4
10
100
0 15 45
chase (min)
%
 re
m
ai
ni
ng
0
2
30
20 4510 0 10    20 45100 20 45 0
DD-Rgs4 DK-Rgs4 DP-Rgs4
chase (min):
1 2 3 4 5 6 7 12111098
DHFR-Ub f
XZ-Rgs4f
DK-Rgs4
DP-Rgs4
DD-Rgs4
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on A
ugust 15, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Fig. 8, Wadas et al.
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B
C
Ate11B7A
Ate11B7B
Ate11A7A
Ate11A7B
A Sequences of 11-residue peptides in panel B (columns 1-12) that are identical
to the N-terminal sequences of mouse proteins or (presumed) natural 
protein fragments that have been reported to be Nt-arginylated in vivo:
1.   DKGLAGLPASC: positive control, bearing a canonical (Nt-arginylatable) N-terminal Asp.
12.    MCDRKAVIKNA: light chain of dynein, bearing N-terminal Met.
3.      LEVLNFFNNQI: fragment of the Ras suppressor protein 1, bearing N-terminal Leu.65
4.      PVLCFTQYEES: fragment of the properdin factor, bearing N-terminal Pro.25
145.      AWGKIGGHGAE: fragment of the hemoglobin alpha-1 chain, bearing N-terminal Ala.
4486.       KPVYDELFYTL: fragment of the protein Mpast2, bearing N-terminal Lys.
437.      GDDGAEYVVES: fragment of a protein similar to GAPDH, bearing N-terminal Gly.
3148.       NSALQCLSNTA: fragment of the ubiquitin-specific protease 4, bearing N-terminal Asn.
909.       FYNELRVAPEE: fragment of beta-actin, bearing N-terminal Phe.
119410.        HSQAVEELADQ: fragment of the non-muscle myosin Myh9, bearing N-terminal His.
20611.       VLVGDVKDRVA: fragment of the PRPPS-1 enzyme, bearing N-terminal Val.
12.  Same as item 1 above: a positive control, bearing the Nt-arginylatable N-terminal Asp.
13 14 15 16 17 18 19 20
Sequences of peptides in panel B, columns 13-20:
58914.      MDPLNDNIATL: fragment of the myosin Myh9, bearing N-terminal Met.
13.  R     MDPLNDNIATL: “arginylated” (during synthesis) counterpart of item 14, below.589
58915.      M(sulfoxide)DPLNDNIATL: fragment of Myh9, bearing N-terminal Met-sulfoxide.
58916.      M(sulfone)DPLNDNIATL: fragment of Myh9, bearing N-terminal Met-sulfone.
17.  ALYENKPRRPY: neurotensin (lacking the last 2 residues and bearing N-terminal Ala
instead of wild-type Gln. The residue in red (Glu-4) was reported to be arginylated in vivo.
18.  Same as item 17 but containing Asp (instead of wild-type Glu) at position 4.
19.  Same as item 17 but containing Asn (instead of wild-type Glu) at position 4.
20.  Same as item 17 but containing Gln (instead of wild-type Glu) at position 4.
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